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Abstract. Background: Increased plasma levels of tissue
inhibitor of metalloproteinases (TIMP-1) are associated with
poor outcome in colorectal cancer (CRC), however
postoperative changes in plasma TIMP-1 levels after
resections for CRC have not been thoroughly evaluated.
Materials and Methods: Plasma samples were collected from
45 patients with primary CRC, preoperatively, 2 hours after
surgery, and at days 1, 2, 7, 28, 45, 60, 75 and 90 after
surgery. TIMP-1 and CEA levels were determined using the
ARCHITECT® Immunoanalyzer. Results: Postoperatively, the
mean (geometric) TIMP-1 level increased and had a
maximum level at day 1 (p<0.0001). The mean TIMP-1 level
then declined to a level at day 90 similar to the mean
preoperative level. Conclusion: A mean decline in plasma
TIMP-1 levels was not observed within 90 days. However,
individual significant reductions of plasma TIMP-1 levels did
occur within 28-60 days postoperatively. 
For patients who have been curatively resected for primary
colorectal cancer (CRC), current international guidelines
recommend postoperative carcinoembryonic antigen (CEA)
testing, clinical evaluation and colonoscopy (1, 2).
Postoperative surveillance has been suggested to improve
survival (3, 4), however, optimal patient follow-up in CRC
remains controversial and its effectiveness is still debated (5-
9). A number of biological markers have been suggested as
additional prognostic factors providing information
independently of the existing grading systems. 
Identification of biological markers capable of early
detection of recurrent or metastatic disease and potentially able
to select patients for adjuvant therapy is greatly needed and
would improve the postoperative surveillance of CRC patients.
Tissue inhibitor of metalloproteinases 1 (TIMP-1) plays a
critical role in normal physiological processes as well as
pathological conditions of tissue remodelling (10). TIMP-1
has been shown to be involved in many different steps of
tumour genesis, inhibition of apoptosis (11, 12), stimulation
of cell growth (13, 14) and the regulation of angiogenesis
(15). In addition, a great number of major clinical studies
have reported a promising prognostic value of tumour tissue
or plasma TIMP-1 measurements in human malignancies
including colorectal cancer, with high TIMP-1 levels
associated with shorter survival (16-23). Plasma TIMP-1
levels have been evaluated during and after major surgery for
CRC and it has been demonstrated that increased
preoperative TIMP-1 levels did not decrease within 30 days
postoperatively, not even in curatively resected patients (24).
However, other results demonstrated that plasma TIMP-1
levels obtained at a median of 7 months postoperatively were
strongly associated with patient outcome, with shorter
survival predicted by high levels of TIMP-1 (25).
To determine whether plasma TIMP-1 is a potential
postoperative surveillance marker in CRC, an assessment of
the postoperative time frame during which the sample should
be collected must be performed. The aim of this study was to
establish the time frame in which postoperative plasma
samples should be collected in order to determine if a patient
was curatively resected or not. Plasma TIMP-1 levels were
compared to plasma levels of CEA.
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Patients and Methods
Patients. In a study approved by the Danish Central National Ethics
Committee, plasma sample sets were prospectively collected
between June 2005 and June 2006 from 82 patients who underwent
resection for primary CRC. Patients who received neoadjuvant,
adjuvant or palliative radio- and/or chemotherapy (within 90 days)
were excluded. The tumour stage was confirmed by histological
examination of the resected tissue. Clinical stage and pathological
features of primary tumours were defined using the TNM system
and converted to stage I-IV (26). After surgical resection, patients
underwent standard treatment and follow-up measures according to
recommended guidelines. At the end of the study, all patient files
were reviewed to detect any local or distant recurrence as well as
any complications to surgery. 
Blood sampling. Peripheral blood samples were obtained with
informed consent from all individuals in agreement with the Helsinki
II Declaration. Blood was drawn preoperatively, 2 hours after
operation and systematically on postoperative days 1, 2, 7, 28, 45, 60,
75 and 90. The samples were collected into silicone-coated endotoxin-
free tubes with EDTA as an anticoagulant (Vacutainers®; Becton-
Dickinson, Mountain View, CA, USA). The sampling, handling,
processing and storage of specimens were performed according to
predefined Standard Operating Procedures previously described (27).
Laboratory methods. Plasma levels of TIMP-1 and CEA were
measured with the Abbott ARCHITECT® i2000 automated
immunoassay utilizing chemiluminescent magnetic particle
immunoassay technology (28). Assays were run at the Abbott
Center of Excellence research laboratory in Amsterdam, the
Netherlands. Abbott in-house research prototype TIMP-1 reagents
(29) and commercial ARCHITECT CEA (30) reagents were used
for these studies. The interassay coefficient of variation (CV) for
this study ranged from 3%  to 6% . The intraassay CV ranged from
2%  to 3% . Additional information concerning the ARCHITECT®
i2000 is thoroughly addressed by Davis et al. (29).
Statistical analysis. The statistical analysis of TIMP-1 was performed
using a linear model with repeated measurements with TIMP-1 on
the log scale, assuming a normal distribution. The analysis was
performed for each stage separately. The change in plasma TIMP-1
level compared to the preoperative level for individual patients was
evaluated using a standard error estimated from 23 healthy
individuals (31). From that study, the intra-individual variance was
estimated and a comparison of a single follow-up measurement to the
preoperative level taken in a short span of time was considered to be
significantly lower if the TIMP-1 levels were reduced by 23%  (one-
sided). The same study also provided an estimation of the mean
(geometric) TIMP-1 level for healthy individuals and the 95%
reference interval (RI) for a single individual. The mean level was
82.0 ng/ml with RI from 59.4 ng/ml to 113.7 ng/ml. TIMP-1 levels
above the upper limit of 113.7 ng/ml were considered elevated.
Although we have previously shown that TIMP-1 is age dependent,
it was not possible to make an age correction in the present study
due to the age range of the healthy individuals.
CEA levels higher than 5.0 ng/ml were defined as elevated. 
P-values less than 5%  were considered significant. All statistical
calculations were made using SAS (Statistical Analysis System,
version 9.1; SAS Institute, Cary, NC, USA).
Results
In total, 45 patients were available for statistical analyses
after implementation of the inclusion and exclusion criteria.
The baseline characteristics of the patients included in the
study are shown in Table I. Not all patients were available
for every sampling time point. In total, a median of 10
samples from each patient was collected (range 7-10
samples), with a median of 90 days (range 45-90 days) of
follow-up. 
TIMP-1. First the time course of pre- to postoperative mean
TIMP-1 levels was evaluated. The preoperative mean levels
(geometric means) of TIMP-1 stratified by stage are shown in
Table II. Table III shows TIMP-1 at significant time points
during the postoperative follow-up as compared to the
preoperative value. TIMP-1 levels above the upper limit of
113.7 ng/ml were considered elevated and a reduction in the
TIMP-1 level by 23%  was considered significant (31). The
analysis was performed for each stage separately. Figure 1
depicts the TIMP-1 level (as a percentage, as a function of the
initial preoperative TIMP-1 level) at day 90 for each patient
with an available blood sample at day 90 and for each stage.
Stage I. Four patients had preoperative TIMP-1 levels
within the predefined RI ranging from 59.4 ng/ml to 113.7
ng/ml. Of the remaining 4 patients with preoperatively
elevated TIMP-1, one patient reached a TIMP-1 level within
the predefined RI at day 28 and the TIMP-1 level further
decreased from day 45 with a 27%  lower level at day 60.
Another patient with preoperative TIMP-1 of 161 ng/ml
showed a 35%  decrease at day 90. A third patient with
preoperativeTIMP-1 of 177 ng/ml had a 23%  decrease, but
did not reach a level below the upper RI limit within the
study period. The fourth patient had elevated TIMP-1 levels
throughout the study period.
Stage II. Individual assessment showed that seven patients
had TIMP-1 levels within the predefined RI prior to operation,
whereas 12 patients had preoperative TIMP-1 levels above the
predefined upper limit of 113.7 ng/ml. Of these 12 patients,
only one with elevated preoperative TIMP-1 of 132 ng/ml had
a statistically significant reduction of 35%  at day 90. 
Stage III. Individual assessment of these patients showed
that six patients had TIMP-1 levels within the predefined RI
at the time of operation. None of the four patients having
elevated TIMP-1 levels preoperatively demonstrated a
significant decrease (>23% ) at any point in time. 
Stage IV. Individual evaluation showed that all stage IV
patients had high levels (>113.7 ng/ml) of TIMP-1
preoperatively. None of these patients demonstrated a
significant reduction in TIMP-1 to a level below the
predefined upper RI. One patient had a statistically significant
53%  reduction from the preoperative level (268 ng/ml)
starting at day 45, which significantly decreased up to day 90.
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Another patient had a postoperative TIMP-1 level reduced by
21%  starting at day 28, which remained at this lower but
elevated level up to day 90. Four of the eight stage IV patients
had TIMP-1 levels that at the end of the study exceeded the
preoperative level.
CEA. A CEA level above the 5.0 ng/ml cut-off value was
considered elevated (32). Table II shows the preoperative
mean levels of CEA stratified by stage. CEA levels at
significant time points during the postoperative follow-up
period relative to preoperative levels are shown in Table III.
Individual assessment of changes in CEA was not performed.
Stage I. Preoperatively, two patients had CEA levels above
the cut-off point of 5.0 ng/ml. CEA levels in these two
patients decreased below the cut-off point. However, at day
90, two other patients had a CEA above the cut-off point.
Stage II. Preoperatively, four of the nineteen patients had
a CEA level above the cut-off point, but they all returned to
levels below this at day 90.
Stage III. Preoperatively, none of the patients in stage III
had levels above the cut-off point and remained below this
throughout the study.
Stage IV. Six patients with preoperatively elevated CEA still
had CEA levels above the cut-off point of 5.0 ng/ml at day 90.
Discussion
The potential value of plasma TIMP-1 as a tumour marker
in CRC has been thoroughly investigated. Preoperative
plasma TIMP-1 has been shown to be elevated in patients
with CRC (16, 18, 33, 34) and preoperative plasma TIMP-1
levels were subsequently shown to hold prognostic
information: high levels were independently related to poor
survival (18, 25, 35, 36). 
Assessment of TIMP-1 after resection of the primary CRC
has also been investigated. It was shown in samples collected
a median 7 months after surgery that patients with high
postoperative plasma TIMP-1 had a significantly shorter
overall survival than patients with low plasma TIMP-1 (25).
Sequential TIMP-1 levels have been determined pre-, intra-
and postoperatively and have shown that the surgical trauma
led to a statistically significant increase day 1 after surgery,
followed by a stepwise decline to levels similar to
preoperative levels on day 30 postoperatively (24). However,
in this time frame, the plasma TIMP-1 levels did not reach a
Frederiksen et al: TIMP-1 after Resection of CRC
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Table I. Baseline characteristics of patients with CRC included in the
study.
Characteristic No. of patients















Table II. The pre-operative levels of TIMP-1 (ng/ml) and CEA (ng/ml)
stratified by stage (geometric mean). 
Stage N Variable Mean Minimum Maximum
I 8 TIMP-1 122.4 90.5 177.3
CEA 3.1 0.6 7.4
II 19 TIMP-1 120.8 77.9 166.2
CEA 2.7 0.5 10.4
III 10 TIMP-1 112.7 81.2 145.0
CEA 2.5 0.8 5.9
IV 8 TIMP-1 201.9 122.0 283.0
CEA 15.7 0.9 165.4
Table III. TIMP-1 and CEA levels at significant time points during the
study as compared with their preoperative value, stratified by stage. 
TIMP-1
Stage N 2 Hours p-value Day 1 p-value Day 90 p-value
1 8 86 0.04 214 <0.0001 97 NS
2 19 94 0.37 187 <0.001 107 NS
3 10 106 NS 220 <0.0001 109 NS
4 8 91 NS 23 <0.0001 97 NS
CEA
Stage N 2 Hours p-value Day 1 p-value Day 90 p-value
1 8 71 0.004 63 <0.0001 83 0.58
2 19 62 <0.0001 77 0.02 74 0.02
3 10 61 <0.0001 61 <0.0001 81 NS
4 8 73 NS 92 NS 31 0.04
NS, non-significant; p-values as compared to preoperative level.
level comparable to plasma TIMP-1 levels found in healthy
individuals. It was suggested that a longer observation time
was needed in order for TIMP-1 to decline to “normal”
levels in patients who were cured by the primary surgery. 
In the present study, pre- and postoperative plasma TIMP-1
levels were evaluated within an extended time frame of up to 3
months in patients resected for primary CRC. Changes in
plasma TIMP-1 levels in peripheral blood were compared to
changes in CEA levels. It was hypothesised that curative
resection of CRC tumours would lead to a postoperative
decrease in plasma TIMP-1 levels reaching the level of plasma
TIMP-1 found in healthy individuals. 
The results showed that preoperatively elevated TIMP-1
levels (above the 113.7 ng/ml) were found in all stages,
although not in all patients. All patients with stage IV disease
had elevated levels of plasma TIMP-1. Two hours
postoperatively, mean plasma TIMP-1 levels demonstrated a
small, non-significant decrease, which may be related to
haemodilution. A significant maximum of mean plasma
TIMP-1 was reached on day 1 postoperatively, independent
of stage. This confirms previous results that TIMP-1
increases dramatically after major surgery (24). At present,
the mechanisms leading to increased TIMP-1 levels
immediately after major surgery are not known in detail.
Disintegration of platelets, neutrophils and macrophages due
to the surgical trauma may play a role in elevation of
postoperative TIMP-1 levels (37, 38). It is worth noticing
that well-established inflammatory mediators such as
interleukin-6 and C-reactive protein also show a
postoperative response similar to that of TIMP-1 (39, 40). 
Following the peak levels at day 1 after surgery, mean
TIMP-1 levels declined gradually throughout the study
period to levels on day 90 which were not significantly
different from preoperative levels. There may be various
explanations why we could not demonstrate a mean decline
of TIMP-1 within 90 days to levels similar to those found in
healthy individuals. The limited number of patients included
with curatively resected disease may play a significant role.
Only 45 out of 82 recruited patients were included in the
final analysis and of these, only 37 underwent intended
curative resection (stage I, II and III). We do not at present
have information on recurrent disease in these patients, but
these data will be obtained when available. Presence of
micrometastatic disease in some of the intended curatively
resected patients may possibly play a role in the observed
limited decrease in postoperative mean TIMP-1 levels. 
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Figure 1. Depicts TIMP-1 levels at day 90 as a function of the initial TIMP-1 level for each patient and each stage.
Additionally, prolonged recovery due to postoperative
infectious and other complications may possibly also play a
role in prolonged increase of plasma TIMP-1 levels. Wound
healing is a complex process involving several phases
including inflammation, proliferation and tissue remodelling,
and matrix metalloproteinases (MMPs) and TIMPs are
required in many of the steps of normal healing (41, 42).
Previous reports have shown that remodelling after wound
healing persists and is not normalized 6 months after surgery
(43) and that differences in TIMP-1 levels postoperatively
were associated with type and length of surgery, blood loss
and postoperative complications (42). Thus, continuous
wound healing with tissue remodelling may explain why
TIMP-1 was not normalized after a follow-up of 90 days. 
We considered whether individual patient assessment of
TIMP-1 levels during the time of observation would provide
additional information. Therefore, we evaluated changes in
TIMP-1 levels for each patient during the study period. We
used a change based on the variability of TIMP-1 estimated
from healthy individuals (95%  RI range 59.4 to 113.7
ng/ml). A reduction by 23%  of the preoperative level was
considered significant. Individual assessment of TIMP-1
levels showed that a number of patients with preoperatively
high plasma TIMP-1 did demonstrate a significant reduction
within the 90 days postoperatively. This significant reduction
of more than 23%  was evident by day 28-60 postoperatively
and the optimal lead-time of postoperative sampling for
plasma TIMP-1 measurements may therefore be within this
time frame. It can be speculated that those patients who
demonstrated a significant postoperative reduction in TIMP-1
could be those that were cured by the surgical intervention,
while patients with no reduction or even an increase in
plasma TIMP-1 postoperatively would be those that later
developed clinically evident recurrent disease. This
hypothesis is supported by a recent study in which it was
shown that patients with elevated plasma TIMP-1 levels 7
months postoperatively had a highly significant risk of early
death (25). A longer observation time will allow us to
correlate the present plasma TIMP-1 findings with the course
of the disease for the individual patients.
As CEA is the most extensively investigated and the only
recommended marker for CRC surveillance, we included CEA
measurements in this study. Current guidelines by ASCO (2)
and EGTM (1) recommend testing of postoperative serum
CEA every 3 months for at least 3 years in patients with stage
II or III disease. In the present study, the mean CEA levels of
patients with stage I, II and III declined immediately following
surgery and continued to decline to day 90, with CEA levels
being significantly lower than the preoperative CEA levels.
Previous studies have shown that elevated CEA concentrations
in CRC patients may persist for up to 5 months (44, 45). Only
six out of the 37 patients in stage I, II and II had CEA levels
above the cut-off point and of these only two had elevated
levels at day 90. Six out of eight patients in stage IV with
preoperative CEA levels above the cut-off point remained
elevated throughout the study. Thus, it is not obvious how
monitoring of postoperative CEA measurements can guide
clinicians as to whether a patient is cured by the primary
surgery, while a further CEA increase postoperatively appears
to be a valid marker of persistent disease or disease recurrence.
In conclusion, it was observed that preoperatively elevated
levels of plasma TIMP-1 were present in all stages, although
not in all patients with CRC. We did not observe a decline
in mean TIMP-1 levels within the 90-day study. However,
when assessing each patient individually, a number of
patients with preoperatively high TIMP-1 did demonstrate a
significant reduction within 28-60 days postoperatively. The
optimal time point for postoperative plasma TIMP-1
sampling appears to be after day 60. Thus, it would be of
interest to perform a clinical study where plasma specimens
for TIMP-1 measurements were collected prior to treatment
and then again following adjuvant chemotherapy to then
determine if patients with persistent or even increasing
TIMP-1 plasma levels were those who later developed
recurrent disease. 
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